The vaccine is personalized to a patient's tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer. The new mRNA vaccine is waiting on FDA approval but has shown great promise in Phase 3 clinical trials. An experimental vaccine offers new hope to patients with melanoma, one of the most aggressive forms of skin cancer . The pharmaceutical companies Merck and Moderna released the results of a Phase 3 clinical trial that evaluated the efficacy of a personalized mRNA-based vaccine that, when combined with immunotherapy, reduced the risk of disease recurrence or death by 42 percent compared to treatment with the immunotherapy drug alone. Georgina Long, medical director of the Australian Melanoma Institute and the study's principal investigator, said in a statement that these results are "transformative" and "have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma."

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW?

Image caption, More than 2,000 images were taken of Ruth's skin I don't mind having my photo taken - triple checked and filtered for Instagram - but 70 cameras pointing at me while I'm down to my knickers is a bit daunting. A robotic voice tells me to stay still and close my eyes as I stand in a huge curved scanner while classical music plays in the background. With a flash of light, 2,000 photographs are taken of my body, in the hope of capturing every mark, freckle and mole to analyse for different skin cancers. This full-body scan is happening at a sci-fi-style clinic in Manchester city centre, with me wearing a dressing gown and hexagon-shaped rubber slippers. The millions of data points collected will create a 3D avatar of my body using AI.

One of the dominant paradigms in self-supervised learning (SSL), illustrated by MoCo or DINO, aims to produce robust representations by capturing features that are insensitive to certain image transformations such as illumination, or geometric changes. This strategy is appropriate when the objective is to recognize objects independently of their appearance. However, it becomes counterproductive as soon as appearance itself constitutes the discriminative signal. In weather analysis, for example, rain streaks, snow granularity, atmospheric scattering, as well as reflections and halos, are not noise: they carry the essential information. In critical applications such as autonomous driving, ignoring these cues is risky, since grip and visibility depend directly on ground conditions and atmospheric conditions. We introduce ST-STORM, a hybrid SSL framework that treats appearance (style) as a semantic modality to be disentangled from content. Our architecture explicitly separates two latent streams, regulated by gating mechanisms. The Content branch aims at a stable semantic representation through a JEPA scheme coupled with a contrastive objective, promoting invariance to appearance variations. In parallel, the Style branch is constrained to capture appearance signatures (textures, contrasts, scattering) through feature prediction and reconstruction under an adversarial constraint. We evaluate ST-STORM on several tasks, including object classification (ImageNet-1K), fine-grained weather characterization, and melanoma detection (ISIC 2024 Challenge). The results show that the Style branch effectively isolates complex appearance phenomena (F1=97% on Multi-Weather and F1=94% on ISIC 2024 with 10% labeled data), without degrading the semantic performance (F1=80% on ImageNet-1K) of the Content branch, and improves the preservation of critical appearance

Deep learning has demonstrated expert-level performance in melanoma classification, positioning it as a powerful tool in clinical dermatology. However, model opacity and the lack of interpretability remain critical barriers to clinical adoption, as clinicians often struggle to trust the decision-making processes of black-box models. To address this gap, we present a Cross-modal Explainable Framework for Melanoma (CEFM) that leverages contrastive learning as the core mechanism for achieving interpretability. Specifically, CEFM maps clinical criteria for melanoma diagnosis-namely Asymmetry, Border, and Color (ABC)-into the Vision Transformer embedding space using dual projection heads, thereby aligning clinical semantics with visual features. The aligned representations are subsequently translated into structured textual explanations via natural language generation, creating a transparent link between raw image data and clinical interpretation. Experiments on public datasets demonstrate 92.79% accuracy and an AUC of 0.961, along with significant improvements across multiple interpretability metrics. Qualitative analyses further show that the spatial arrangement of the learned embeddings aligns with clinicians' application of the ABC rule, effectively bridging the gap between high-performance classification and clinical trust.

Accurate and timely diagnosis of multi-class skin lesions is hampered by subjective methods, inherent data imbalance in datasets like HAM10000, and the "black box" nature of Deep Learning (DL) models. This study proposes a trustworthy and highly accurate Computer-Aided Diagnosis (CAD) system to overcome these limitations. The approach utilizes Deep Convolutional Generative Adversarial Networks (DCGANs) for per class data augmentation to resolve the critical class imbalance problem. A fine-tuned ResNet-50 classifier is then trained on the augmented dataset to classify seven skin disease categories. Crucially, LIME and SHAP Explainable AI (XAI) techniques are integrated to provide transparency by confirming that predictions are based on clinically relevant features like irregular morphology. The system achieved a high overall Accuracy of 92.50 % and a Macro-AUC of 98.82 %, successfully outperforming various prior benchmarked architectures. This work successfully validates a verifiable framework that combines high performance with the essential clinical interpretability required for safe diagnostic deployment. Future research should prioritize enhancing discrimination for critical categories, such as Melanoma NOS (F1-Score is 0.8602).

We propose a Bayesian decision making framework for control of Markov Decision Processes (MDPs) with unknown dynamics and large, possibly continuous, state, action, and parameter spaces in data-poor environments. Most of the existing adaptive controllers for MDPs with unknown dynamics are based on the reinforcement learning framework and rely on large data sets acquired by sustained direct interaction with the system or via a simulator. This is not feasible in many applications, due to ethical, economic, and physical constraints. The proposed framework addresses the data poverty issue by decomposing the problem into an offline planning stage that does not rely on sustained direct interaction with the system or simulator and an online execution stage. In the offline process, parallel Gaussian process temporal difference (GPTD) learning techniques are employed for near-optimal Bayesian approximation of the expected discounted reward over a sample drawn from the prior distribution of unknown parameters. In the online stage, the action with the maximum expected return with respect to the posterior distribution of the parameters is selected. This is achieved by an approximation of the posterior distribution using a Markov Chain Monte Carlo (MCMC) algorithm, followed by constructing multiple Gaussian processes over the parameter space for efficient prediction of the means of the expected return at the MCMC sample. The effectiveness of the proposed framework is demonstrated using a simple dynamical system model with continuous state and action spaces, as well as a more complex model for a metastatic melanoma gene regulatory network observed through noisy synthetic gene expression data.

Artificial Intelligence (AI) models have demonstrated expert-level performance in melanoma detection, yet their clinical adoption is hindered by performance disparities across demographic subgroups such as gender, race, and age. Previous efforts to benchmark the performance of AI models have primarily focused on assessing model performance using group fairness metrics that rely on the Area Under the Receiver Operating Characteristic curve (AUROC), which does not provide insights into a model's ability to provide accurate estimates. In line with clinical assessments, this paper addresses this gap by incorporating calibration as a complementary benchmarking metric to AUROC-based fairness metrics. Calibration evaluates the alignment between predicted probabilities and observed event rates, offering deeper insights into subgroup biases. We assess the performance of the leading skin cancer detection algorithm of the ISIC 2020 Challenge on the ISIC 2020 Challenge dataset and the PROVE-AI dataset, and compare it with the second and third place models, focusing on subgroups defined by sex, race (Fitzpatrick Skin Tone), and age. Our findings reveal that while existing models enhance discriminative accuracy, they often over-diagnose risk and exhibit calibration issues when applied to new datasets. This study underscores the necessity for comprehensive model auditing strategies and extensive metadata collection to achieve equitable AI-driven healthcare solutions. All code is publicly available at https://github.com/bdominique/testing_strong_calibration.

As machine learning systems become increasingly integrated into human-centered domains such as healthcare, ensuring fairness while maintaining high predictive performance is critical. Existing bias mitigation techniques often impose a trade-off between fairness and accuracy, inadvertently degrading performance for certain demographic groups. In high-stakes domains like clinical diagnosis, such trade-offs are ethically and practically unacceptable. In this study, we propose a fairness-without-harm approach by learning distinct representations for different demographic groups and selectively applying demographic experts consisting of group-specific representations and personalized classifiers through a no-harm constrained selection. We evaluate our approach on three real-world medical datasets -- covering eye disease, skin cancer, and X-ray diagnosis -- as well as two face datasets. Extensive empirical results demonstrate the effectiveness of our approach in achieving fairness without harm.

The skin is the largest organ in the human body, and approximately a third of the total number of cancer cases are represented by skin cancers. Melanoma is the deadliest form of skin cancer, which is responsible for an overwhelming majority of skin cancer deaths. The number of melanoma deaths is expected to increase by 4.4% in 2023. Although the mortality is significant, when detected e arly, the 5-year survival rate for melanoma is over 99% (American Cancer Society, 2022). Currently, the most accurate way to diagnose melanoma is a biopsy. This is a penetrative surgical procedure that involves higher costs but also incorporates risks of developing various infectious diseases (Lakhtakia et al., 2009). Thus, the usual clinical practice of melanoma diagnosis is visual inspection using Dermoscopy by dermatologists or specially trained clinicians. This approach presents challenges, primarily due to its resource-intensive nature in terms of time and cost. This method's accuracy of melanoma diagnosis is approximately